These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
329 related items for PubMed ID: 9323935
21. Tissue factor increases in the aqueous humor of proliferative diabetic retinopathy. Sakamoto T, Ito S, Yoshikawa H, Hata Y, Ishibashi T, Sueishi K, Inomata H. Graefes Arch Clin Exp Ophthalmol; 2001 Nov; 239(11):865-71. PubMed ID: 11789868 [Abstract] [Full Text] [Related]
23. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Joussen AM, Poulaki V, Qin W, Kirchhof B, Mitsiades N, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP. Am J Pathol; 2002 Feb; 160(2):501-9. PubMed ID: 11839570 [Abstract] [Full Text] [Related]
24. Angiotensin AT(1) receptor antagonism normalizes retinal blood flow and acetylcholine-induced vasodilatation in normotensive diabetic rats. Horio N, Clermont AC, Abiko A, Abiko T, Shoelson BD, Bursell SE, Feener EP. Diabetologia; 2004 Jan; 47(1):113-23. PubMed ID: 14618237 [Abstract] [Full Text] [Related]
25. Evaluating retinal circulation using video fluorescein angiography in control and diabetic rats. Bursell SE, Clermont AC, Shiba T, King GL. Curr Eye Res; 1992 Apr; 11(4):287-95. PubMed ID: 1388117 [Abstract] [Full Text] [Related]
26. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Hogeboom van Buggenum IM, Polak BC, Reichert-Thoen JW, de Vries-Knoppert WA, van Hinsbergh VW, Tangelder GJ. Diabetologia; 2002 Feb; 45(2):203-9. PubMed ID: 11935151 [Abstract] [Full Text] [Related]
28. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G. Diabetes; 1998 Mar; 47(3):401-6. PubMed ID: 9519746 [Abstract] [Full Text] [Related]
31. Correlation of retinal vascular perfusion density with dark adaptation in diabetic retinopathy. Hsiao CC, Hsu HM, Yang CM, Yang CH. Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1401-1410. PubMed ID: 31001668 [Abstract] [Full Text] [Related]
32. Quantitative MR imaging study of intravitreal sustained release of VEGF in rabbits. Alikacem N, Yoshizawa T, Nelson KD, Wilson CA. Invest Ophthalmol Vis Sci; 2000 May; 41(6):1561-9. PubMed ID: 10798677 [Abstract] [Full Text] [Related]
35. Intravitreal injection of erythropoietin protects against retinal vascular regression at the early stage of diabetic retinopathy in streptozotocin-induced diabetic rats. Mitsuhashi J, Morikawa S, Shimizu K, Ezaki T, Yasuda Y, Hori S. Exp Eye Res; 2013 Jan; 106():64-73. PubMed ID: 23178551 [Abstract] [Full Text] [Related]
39. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Tilton RG, Chang KC, LeJeune WS, Stephan CC, Brock TA, Williamson JR. Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):689-96. PubMed ID: 10067972 [Abstract] [Full Text] [Related]